⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Maruishi Pharmaceutical Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Maruishi Pharmaceutical Co., Ltd.
↗Osaka, Japan
Maruishi Pharmaceutical is a Japanese specialty pharmaceutical company with a history dating back to 1888. It focuses on the research, development, and commercialization of drugs primarily in the perioperative, infection control, acute care, and cancer supportive care fields.
The company is well-regarded for its expertise in anesthetics, analgesics, sedatives, and antiseptics/disinfectants. It actively engages in both in-house R&D and strategic collaborations with international biotechnology and pharmaceutical firms to bring innovative therapies to the Japanese market.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:-
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharma (Perioperative/Acute Care)
SIZE & FINANCIALS
Employees:201-500
Revenue:$300M-$350M
Founded:1888
Ownership:private
Status:operating
PIPELINE
Stage:Phase 2
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:13
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Allay Therapeutics (ATX101 for post-surgical pain), Cara Therapeutics (Difelikefalin/KORSUVA), Kissei Pharmaceutical (Joint development of KORSUVA)
COMPETITION
Position:Niche Player
Competitors:Daiichi Sankyo, Kissei Pharmaceutical, Teikoku Pharma, Meiji Seika Pharma
LEADERSHIP
Key Executives:
Katsuhito Inoue - President and Representative Director
LINKS
Website:maruishi-pharm.co.jp
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Maruishi Pharmaceutical Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.